Increasing prevalence of infectious diseases worldwide is propelling the demand for anti-infective agents. Moreover, the rise in geriatric population and increasing awareness about healthcare are driving market growth. Additionally, advancements in technology and research for the development of novel anti-infective drugs are creating lucrative opportunities for market players.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Type/Drug Class, Route Of Administration, Distribution Channel |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Pfizer, Abbott, Gilead Sciences,, Bristol-Myers Squibb Company, Merck & Co.,, Sandoz International, B. Braun SE, Xellia Pharmaceuticals, Mankind Pharma, Bayer AG, AstraZeneca, Boehringer Ingelheim International |
However, stringent regulatory requirements and lengthy approval processes are major restraints hindering the growth of the anti-infective agents market. Moreover, the increasing prevalence of antibiotic resistance is also posing a challenge for market growth.